Resumen
Psychosis and hyperactive behaviors, such as agitation and wandering, affect a significant proportion of patients with Alzheimer’s disease (AD). These symptoms are often treated with antipsychotics, usually in an off-label approach. This mini-review provides an updated perspective on the pharmacological approach for the neuropsychiatric symptoms (NPS) in AD. The results of new studies have provided a better understanding of AD-related NPS management, but high-quali-ty evidence still needs to be obtained. Herein, we argue for a more cautious approach to the use of antipsychotics in AD and highlight the importance of exploring alternative treatments for NPS. By doing so, we can ensure that patients with AD receive optimal care that is both effective and safe.
| Idioma original | English (US) |
|---|---|
| Páginas (desde-hasta) | 682-691 |
| Número de páginas | 10 |
| Publicación | Current Alzheimer Research |
| Volumen | 20 |
| N.º | 10 |
| DOI | |
| Estado | Published - 2023 |
ASJC Scopus subject areas
- General Medicine
Huella
Profundice en los temas de investigación de 'Antipsychotics in Alzheimer’s Disease: Current Status and Therapeutic Alternatives'. En conjunto forman una huella única.Citar esto
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS